Expression and clinical significance of C1orf63 in breast cancer / 国际肿瘤学杂志

Objective To investigate the expression and clinical significance of C1orf63 in breast cancer.Methods Sixty-seven breast cancer tissues and adjacent non-cancerous tissues were collected,and the expression of C1orf63 was detected by immunohistochemistry.The relationships between C1orf63 and clinical pathological characteristics were examined withx2 test.Independent prognostic factors were performed by theCox regression model.Results Positive cytoplasmic expression of C1orf63 was observed in 21 (31.3％) of 67 primary tumors,but not in their matched adjacent non-cancerous tissues,with significant difference (x2 =24.90,P ＜ 0.01).There were no relationships between C1orf63 and age (x2 =0.06,P =0.79),T stage (x2 =0.50,P =0.47),N stage (x2 =1.41,P =0.23),TNM stage (x2 =0.29,P =0.58),estrogen receptor (x2=0.82,P =0.36),progesterone receptor (x2=0.31,P =0.57),and human epidermal growth factor receptor 2 (Her2) expression (x2 =0.00,P =0.98).Multivariate analysis demonstrated N stage (HR =4.96,95％CI:2.03-12.15,P＜0.01) and C1orf63 (HR=2.37,95％CI:1.05-5.37,P=0.04) were unfavorable prognostic factors.Conclusion The high expression of C1orf63 in breast cancer may indicate poor prognosis.

Clinical value of combining indocyanine green fluorescence navigation with blue dye in sentinel lymph node biopsy in patients with breast cancer / 中国肿瘤临床

Objective:To examine the clinical value of combining indocyanine green (ICG) fluorescence navigation with blue dye in sen-tinel lymph node biopsy (SLNB) for patients with breast cancer. Methods:A total of 89 patients with early-stage breast cancer who met the inclusion criteria were admitted at Shantou Central Hospital, Guangdong from May 2013 to April 2014. In phase one, ICG and blue dye were applied in all 53 patients, and then SLNB and axillary lymph node dissection (ALND) were performed based on fluores-cence signal or visual sense of the lymph nodes. In phase two, 36 patients with early-stage breast cancer were included. ALND was omitted when sentinel lymph nodes were frozen showing negative result. Rates of detection, accuracy, and false-negative were calcu-lated. Results:A total of 89 patients were monitored, of which the total rate of SLNB detection was 96.6%(86/89). In the validation pe-riod, the rates of detection, accuracy, and false-negative were 94.3%(50/53) 98.0%(49/50), and 2.6%(1/38), respectively. In the alter-ative period, the rates of detection reached 100%. Of the 196 sentinel lymph nodes, 179 showed fluorescence signal, 142 exhibited blue dying, 54 only demonstrated fluorescence signals, and 45 demonstrated metastasis with five signaling fluorescence. About 24.7%of patients were diagnosed with SLN metastasis (22/89), where SLNB in two patients showed fluorescence signal but without blue dye. No ipsilateral lymph node relapsed were observed during a median follow up of 25 months. Conclusion:Combination of ICG fluores-cence navigation with blue dye in SLNB is safe for patients with breast cancer.

Second line treatment of non-small cell lung cancer / 国际肿瘤学杂志

The cytotoxic agents pemetrexed and docetaxel and the epidermal growth factor receptor (EGFR)tyrosine kinase inhibitors(TKIs)erlotinib and gefitinib are standard second-line therapies for non-small cell lung cancer. For patients without the EGFR mutation,more and more evidence has suggested the superiority of chemotherapy over targeted therapy. Adding targeted agents to standard second-line treatment is an trend of exploration,but without promising results nowadays. Crizotinib,targeting at anaplastic lymphoma kinase,has been shown excellent efficacy for second-line therapy in non-small cell lung cancer.

Phase Ⅱ trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma / 肿瘤研究与临床

Objective To evaluate the effects of antitumor,toxicity and survival of second-line chemotherapy with docetaxel and capecitabine in patients with advanced esophageal squamous cell carcinoma.Methods Thirty eligible patients with measurable lesions received 1-hour intravenous treatment of docetaxel (60 mg/m2 on day 1) plus oral capecitabine (825 mg/m2 twice daily on days 1-14) every 3 weeks for up to 6 cycles.Results Patients received a median of two cycles of treatment (range 2-6).The median follow-up interview was 15.4 months (3.0-31.5 months).Intent-to-treat efficacy analysis demonstrated an overall response rate of 23.3 ％ (0 complete and 7 partial) and stability of 43.3 ％ (13 cases).The median time to progression was 3.0 months (95 ％ CI 1.929-4.071).The median survival was 8.3 months (95 ％ CI6.848-9.752).Severe adverse events (grade 3/4) reported were neutropenia (10 cases),anaemia (5 cases),thrombocytopenia (3 cases),hand-foot syndrome (4 cases),and fatigue (3 cases).Conclusion Docetaxel plus capecitabine have a manageable adverse event profile and promising activity in advance esophageal squamous cell carcinoma as a second-line treatment.

Targeted therapy of metastatic renal cell cancer / 国际肿瘤学杂志

Targeted therapy of anti-angiogensis strategy is the standard treatment for metastatic renal cell cancer.In recent years,a number of new generation of anti-angiogensis agents have been tested in clinical trials,some of which have achieved promising outcomes.Other pathway inhibitors such as inhibitors of mamma-lian target of rapamycin and fibroblast growth factor receptor pathway have made progresses in some extent.

Roles of bisphosphonate in the adjuvant treatment of breast cancer / 国际肿瘤学杂志

Bisphosphonates are commonly used in patients with breast cancer to reduce skeletal-related events in metastatic disease,mitigate bone loss,and increase bone mineral density.Bisphosphonates can decrease and cleare disseminated tumor cells in bone marrow and circulation tumor cells and then prevent breast cancer relapse and metastases.Bisphosphonates can lighten tumor burden in the breast when administered with neoadjuvant chemotherapy,and improve pathology complete remission rates.Inconsistence is observed in large trials using bisphosphonates in the adjuvant setting of early breast cancer,but survival improvement is mostly seen in postmenopausal patients with low levels of estrogens.

Anti-tumor clinical research of mTOR inhibitor / 国际肿瘤学杂志

In recent years,mTOR inhibitors such as temsirolimus and everolimus are considered to be effective as a new generation of anti-tumor agent.Their efficacies are proven by a number of clinical trials especially in the field of overcoming the drug resistance of tumor cells.But the optimal combination regimen of the mTOR inhibitors and other anti-tumor drugs is still to be validated.

Advances in the antitumor research of PARP inhibitor / 国际肿瘤学杂志

Poly ADP-Ribose Polymerase(PARP)plays an important role in the detection and repair of DNA damage.Inhibition of the PARP activity in the homologous-recombination defective cancer cell could lead to genomic instability and ultimately cause cell death.In preclinical study PARP inhibitors have demonstrated the capacity of enhancing sensitivity of cancel cells to chemotherapy agents and radiation.PARP inhibitors also showed antitumour potential in early clinical trials as monotherapy or combined with chemotherapy.

Current research status of TOP2A gene with response to anthracycline-based chemotherapeutic agents in breast cancer / 国际肿瘤学杂志

Anthracycline-based chemotherapeutic agents were extensively applied to the treatment of breast cancer. The relation of its response to TOP2A gene was proved by a number of clinical studies demonstrating that patients with both HER2 gene amplification and TOP2A gene aberration have a favored outcome,but a consensus was not yet achieved.

Medical therapy of advanced biliary tract cancer / 国际肿瘤学杂志

Medical therapy is the primary choice for patients with advanced biliary tract cancer.Gemcitabine has been proved to be one of the most effective drugs and a standard regimen has been made when combined with cisplatin.Studies of the second line therapy is few.Targeted therapy has a potential to create a new era in the future but needs to be validated in large clinical trials.

Medical treatment of advanced esophageal cancer / 国际肿瘤学杂志

Cisplatin in combination with fluorouracil still is considered as the basic therapeutic scheme for advanced esophageal cancer. New cytotoxic drugs, such as taxanes and topoisomerase inhibitor etc, and new regimens are focus researches for medical treatment. Intravenous fluorouracil can be replaced by oral fluorouracil derivative, and cisplatin can be replaced by oxaliplatin in the regimens of contained cisplatin and fluorouracil for advanced esophageal cancer. Patients with advanced esophageal cancer are now offered seconded line treatment, and the number of research protocols is increasing. Molecule targeted therapy as a promising treatment will provide more and better options for patients.

Progress in multidisciplinary treatment of resectable esophageal cancer / 国际肿瘤学杂志

In recent years, there has been a gradual increase in treatment options for patients with esophageal cancer. While surgery remains to be the primary treatment, neoadjuvant and adjuvant therapy, both preoperatively and postoperatively, have become more important in the multidisciplinary treatment of resectable esophageal cancer. Definitive concomitant chemo-radiotherapy may replace surgery as the primary treatment for resectable esophageal cancer. Cisplatin combined with 5-fluorouracil remains the backbone regimen for neoadjuvant and adjuvant therapy. Intense researches are underway to investigate new cytotoxic drugs such as taxanes and topoisomerase inhibitor, and new regimens for perioperative treatment of resectable esophageal cancer.